As of November 6, 2026, Monte Rosa Therapeutics, Inc. is a publicly traded company (Nasdaq: GLUE). The largest holder reporting an active stake on Schedule 13D is New Enterprise Associates 17, L.P., at 7.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include T. Rowe Price (10.5%), Baker Bros. Advisors LP (9.99%), Adam Goulburn (8.1%) (Schedule 13D/A, July 6, 2026).
Is this your company?
About to sign with, pay or invest in Monte Rosa Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Monte Rosa Therapeutics, Inc. a real, registered company?
- Monte Rosa Therapeutics, Inc. files with the SEC under CIK 1826457 (its SEC filings).
- Its shares are listed under the ticker GLUE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Monte Rosa Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vestal Point Capital, LP (filed 2026-08-14).
Who are Monte Rosa Therapeutics, Inc.'s owners and officers?
Monte Rosa Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Montanova Capital, LLC | 4.2% |
| Schedule 13G, 2026-08-14 | Vestal Point Capital, LP | 5.4% |
| Schedule 13G/A, 2026-07-08 | T. Rowe Price Associates, Inc. | 10.5% |
| Schedule 13D/A, 2026-07-06 | New Enterprise Associates 17, L.P. | 7.9% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 6.3% |
| Schedule 13G/A, 2026-05-15 | Baker Bros. Advisors LP | 9.99% |
| Schedule 13G/A, 2026-05-15 | Chen Yu | 5.5% |
| Schedule 13G/A, 2026-04-22 | Adam Goulburn | 8.1% |
| Schedule 13D/A, 2026-03-19 | New Enterprise Associates 17, L.P. | 9.7% |
| Schedule 13G/A, 2026-02-17 | Baker Bros. Advisors LP | 6.7% |
| Schedule 13G/A, 2026-02-17 | Bvf Partners L P/Il | 5.9% |
| Schedule 13G/A, 2026-01-21 | Adam Goulburn | 8.7% |
Questions about who owns Monte Rosa Therapeutics, Inc.
Who owns Monte Rosa Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Monte Rosa Therapeutics, Inc.: T. Rowe Price Associates, Inc. (10.5%, Schedule 13G/A, filed 2026-07-08), Baker Bros. Advisors LP (9.99%, Schedule 13G/A, filed 2026-05-15), Adam Goulburn (8.1%, Schedule 13G/A, filed 2026-04-22), New Enterprise Associates 17, L.P. (7.9%, Schedule 13D/A, filed 2026-07-06) and Bvf Partners L P/Il (6.3%, Schedule 13G/A, filed 2026-05-15); 2 more are listed above.
Who are the largest shareholders of Monte Rosa Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Monte Rosa Therapeutics, Inc. on this page are T. Rowe Price Associates, Inc. (10.5%), Baker Bros. Advisors LP (9.99%) and Adam Goulburn (8.1%).
When did T. Rowe Price Associates, Inc. buy into Monte Rosa Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Associates, Inc. on this page is the Schedule 13G/A, filed 2026-07-08, reporting 10.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Monte Rosa Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Monte Rosa Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monte Rosa Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Monte Rosa Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Versant Vantage I GP-GP, LLC, a 10% owner: 7,241,975 shares (8.5% of shares outstanding), 4,079,469 held directly and 3,162,506 indirectly, on a joint filing (Form 4, 2024-10-30).
- Versant Vantage I GP, L.P., a 10% owner: 7,241,975 shares (8.5% of shares outstanding), 4,079,469 held directly and 3,162,506 indirectly, on a joint filing (Form 4, 2024-10-30).
- Versant Ventures VI GP, L.P., a 10% owner: 7,241,975 shares (8.5% of shares outstanding), 4,079,469 held directly and 3,162,506 indirectly, on a joint filing (Form 4, 2024-10-30).
- Versant Ventures VI GP-GP, LLC, a 10% owner: 7,241,975 shares (8.5% of shares outstanding), 4,079,469 held directly and 3,162,506 indirectly, on a joint filing (Form 4, 2024-10-30).
- Versant Venture Capital VI, L.P., a 10% owner: 7,241,975 shares (8.5% of shares outstanding), 4,079,469 held directly and 3,162,506 indirectly, on a joint filing (Form 4, 2024-10-30).
Shares outstanding: 85,450,119 as of 2026-10-30, from the company's latest SEC cover page.
How much has Monte Rosa Therapeutics, Inc. raised?
No fundraising or offering filing from Monte Rosa Therapeutics, Inc. is on file with us.
Keep reading
More on Monte Rosa Therapeutics, Inc. and the records around it.
Monte Rosa Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), LENZ Therapeutics, Inc. (Nov 2025), LAVA Therapeutics N.V. (Sep 2025)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026), SpyGlass Pharma, Inc. (Feb 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/monte-rosa-therapeutics